The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 9, 2014, Pages

  Juul, Kristian Vinter ^a   Bichet, Daniel G ^b   Nielsen, Søren ^c   Nørgaard, Jens Peter ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Arginine vasopressin; Desmopressin

Indexed keywords

AQUAPORIN 2; BLOOD CLOTTING FACTOR; EPITHELIAL SODIUM CHANNEL; SODIUM CHLORIDE; UREA; VASOPRESSIN V2 RECEPTOR; WATER;

HUMAN; KIDNEY COLLECTING TUBULE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; VASODILATATION;

ARGININE VASOPRESSIN; ARGININE VASOPRESSIN V2 RECEPTOR; DESMOPRESSIN; EXTRARENAL VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMALS; CYCLIC AMP; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HORMONE ANTAGONISTS; HUMANS; KIDNEY; MALE; PHENOTYPE; RECEPTORS, VASOPRESSIN; SIGNAL TRANSDUCTION; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 84900551850     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00604.2013     Document Type: Review

References (135)

1. Alonso G, Galibert E, Boulay V, Guillou A, Jean A, Compan V, Guillon G. Sustained elevated levels of circulating vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors. Endocrinology 150: 239-250, 2009.
2. Antoni FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 39: 186-188, 1984.
3. Bankir L, Bichet DG, Bouby N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Renal Physiol 299: F917-F928, 2010.
4. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol 16: 1920-1928, 2005.
5. Barberis C, Audigier S. Vasopressin and oxytocin receptors in the central nervous system of the rat. Ann Endocrinol (Paris) 46: 35-39, 1985.
6. Beckwith BE, Petros TV, Bergloff PJ, Staebler RJ. Vasopressin analogue (dDAVP) facilitates recall of narrative prose. Behav Neurosci 101: 429-432, 1987.
7. Belokoskova SG, Stepanov II, Tsikunov SG. Agonist of V2 vasopressin receptor reduces depressive disorders in post-stroke patients. Vestn Ross Akad Med Nauk: 40-44, 2012.
8. Berglund L, Björling E, Oksvold P, Fagerberg L, Asplund A, Szigyarto CA, Persson A, Ottosson J, Wernérus H, Nilsson P, Lundberg E, Sivertsson A, Navani S, Wester K, Kampf C, Hober S, Pontén F, Uhlén M. A genecentric human protein atlas for expression profiles based on antibodies. Mol Cell Proteomics 7: 2019-2027, 2008.
9. Berletch JB, Yang F, Xu J, Carrel L, Disteche CM. Genes that escape from X inactivation. Hum Genet 130: 237-245, 2011.
10. Bichet DG. V2R mutations and nephrogenic diabetes insipidus. Prog Mol Biol Transl Sci 89: 15-29, 2009.
11. Bichet DG. Genetics and diagnosis of central diabetes insipidus. Ann Endocrinol (Paris) 73: 117-127, 2012.
12. Bichet DG, Razi M, Arthus MF, Lonergan M, Tittley P, Smiley RK, Rock G, Hirsch DJ. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism. Kidney Int 36: 859-866, 1989.
13. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 318: 881-887, 1988.
14. Born J, Pietrowsky R, Fehm HL. Neuropsychological effects of vasopressin in healthy humans. Prog Brain Res 119: 619-643, 1998.
15. Bouley R, Lin HY, Raychowdhury MK, Marshansky V, Brown D, Ausiello DA. Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway. Am J Physiol Cell Physiol 288: C1390-C1401, 2005.
16. Boyd JH, Holmes CL, Wang Y, Roberts H, Walley KR. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 79: 325-331, 2008.
17. Caldwell HK, Lee H, Macbeth AH, Young WS. Vasopressin: behavioral roles of an "original" neuropeptide. Prog Neurobiol 84: 1-24, 2008.
18. Carpentier E, Greenbaum LA, Rochdi D, Abrol R, Goddard WA, Bichet DG, Bouvier M. Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol 23: 1635-1640, 2012.
19. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434: 400-404, 2005.
20. 2+ in rat medullary collecting tubules. Am J Physiol Renal Fluid Electrolyte Physiol 265: F35-F45, 1993.
21. Charest PG, Oligny-Longpré G, Bonin H, Azzi M, Bouvier M. The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal 19: 32-41, 2007.
22. Chou C, Christensen BM, Frische S, Vorum H, Desai RA, Hoffert JD, de Lanerolle P, Nielsen S, Knepper MA. Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct. J Biol Chem 279: 49026-49035, 2004.
23. 2+ stores and calmodulin. J Biol Chem 275: 36839-36846, 2000.
24. Colombo P, Passini E, Re T, Faglia G, Ambrosi B. Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess. Clin Endocrinol (Oxf) 46: 661-668, 1997.
25. Cristià E, Amat C, Naftalin RJ, Moretó M. Role of vasopressin in rat distal colon function. J Physiol 578: 413-424, 2007.
26. De Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, Clauser E. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 356: 215-220, 1994.
27. De Minteguiaga C, Clerget MS, Tran Ba Huy P, Elalouf JM. Beta2-adrenergic but not vasopressin V2 receptor mRNAs are expressed in the stria vascularis of the rat inner ear. Pflügers Arch 436: 940-947, 1998.
28. Demura M, Takeda Y, Yoneda T, Oda N, Bando Y, Mabuchi H. Surgical stress-induced transient nephrogenic diabetes insipidus (NDI) associated with decreased vasopressin receptor 2 (AVPR2) expression linked to nonsense-mediated mRNA decay and incomplete skewed x-inactivation in a female patient with a heterozygous AVPR2 mutation (c. 89-90 delAC). Clin Endocrinol (Oxf) 60: 773-775, 2004.
29. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322: 900-904, 2008.
30. Douglass J, Gunaratne R, Bradford D, Saeed F, Hoffert JD, Steinbach PJ, Knepper MA, Pisitkun T. Identifying protein kinase target preferences using mass spectrometry. Am J Physiol Cell Physiol 303: C715-C727, 2012.
31. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G proteincoupled receptors. Circ Res 99: 570-582, 2006.
32. Dóczi T, Szerdahelyi P, Gulya K, Kiss J. Brain water accumulation after the central administration of vasopressin. Neurosurgery 11: 402-407, 1982.
33. Ecelbarger CA, Chou CL, Lolait SJ, Knepper MA, DiGiovanni SR. Evidence for dual signaling pathways for V2 vasopressin receptor in rat inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 270: F623-F633, 1996.
34. Feinstein TN, Yui N, Webber MJ, Wehbi VL, Stevenson HP, King JDJ, Hallows KR, Brown D, Bouley R, Vilardaga J. Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem 288: 27849-27860, 2013.
35. Forti FL, Armelin HA. Arginine vasopressin controls p27(Kip1) protein expression by PKC activation and irreversibly inhibits the proliferation of K-Ras-dependent mouse Y1 adrenocortical malignant cells. Biochim Biophys Acta 1813: 1438-1445, 2011.
36. Fujiwara M, Ohgami Y, Inada K, Iwasaki K. Effect of active fragments of arginine-vasopressin on the disturbance of spatial cognition in rats. Behav Brain Res 83: 91-96, 1997.
37. Furuta H, Luo L, Ryan AF, Mori N. Expression of mRNA encoding vasopressin V1a, vasopressin V2, and ANP-B receptors in the rat cochlea. Hear Res 117: 140-148, 1998.
38. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 361: 549-552, 1993.
39. Gentilini D, Castaldi D, Mari D, Monti D, Franceschi C, Di Blasio AM, Vitale G. Age-dependent skewing of X chromosome inactivation appears delayed in centenarians' offspring. Is there a role for allelic imbalance in healthy aging and longevity? Aging Cell 11: 277-283, 2012.
40. Gold PW, Weingartner H, Ballenger JC, Goodwin FK, Post RM. Effects of 1-desamo-8-D-arginine vasopressin on behaviour and cognition in primary affective disorder. Lancet 2: 992-994, 1979.
41. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer 46: 547-553, 2006.
42. Hall DA, Varney DM. Effect of vasopressin on electrical potential difference and chloride transport in mouse medullary thick ascending limb of henle's loop. J Clin Invest 66: 792-802, 1980.
43. Heard E, Clerc P, Avner P. X-chromosome inactivation in mammals. Annu Rev Genet 31: 571-610, 1997.
44. Hebert SC, Andreoli TE. Control of NaCl transport in the thick ascending limb. Am J Physiol Renal Fluid Electrolyte Physiol 246: F745-F756, 1984.
45. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 6: 2499-2507, 2011.
46. Hirasawa A, Nakayama Y, Ishiharada N, Honda K, Saito R, Tsujimoto G, Takano Y, Kamiya H. Evidence for the existence of vasopressin V2 receptor mRNA in rat hippocampus. Biochem Biophys Res Commun 205: 1702-1706, 1994.
47. Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE, Alonso DF. Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. Future Med Chem 3: 1987-1993, 2011.
48. Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80: 295-301, 2011.
49. Izumi Y, Hori K, Nakayama Y, Kimura M, Hasuike Y, Nanami M, Kohda Y, Otaki Y, Kuragano T, Obinata M, Kawahara K, Tanoue A, Tomita K, Nakanishi T, Nonoguchi H. Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis. J Am Soc Nephrol 22: 673-680, 2011.
50. Jard S. Vasopressin receptors. A historical survey. Adv Exp Med Biol 449: 1-13, 1998.
51. Jenkins JS, Mather HM, Coughlan AK. Effect of desmopressin on normal and impaired memory. J Neurol Neurosurg Psychiatry 45: 830-831, 1982.
52. Juul KV, Erichsen L, Robertson GL. Temporal delays and individual variation in antidiuretic response to desmopressin. Am J Physiol Renal Physiol 304: F268-F278, 2013.
53. Juul KV, Klein BM, Nørgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn 32: 363-370, 2013.
54. Kato Y, Igarashi N, Hirasawa A, Tsujimoto G, Kobayashi M. Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation 59: 163-169, 1995.
55. Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (dDAVP) induces NO production in human endothelial cells via V2 receptor-and cAMPmediated signaling. J Thromb Haemost 1: 821-828, 2003.
56. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin-induced von willebrand factor secretion from endothelial cells involves V2 receptors and camp. J Clin Invest 106: 107-116, 2000.
57. Keegan BP, Akerman BL, Péqueux C, North WG. Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies. Breast Cancer Res Treat 95: 265-277, 2006.
58. Kirk CJ, Verrinder TR, Hems DA. Rapid stimulation, by vasopressin and adrenaline, of inorganic phosphate incorporation into phosphatidyl inositol in isolated hepatocytes. FEBS Lett 83: 267-271, 1977.
59. Kitano H, Suzuki M, Kitanishi T, Yazawa Y, Kitajima K, Isono T, Takeda T, Kimura H, Tooyama I. Regulation of inner ear fluid in the rat by vasopressin. Neuroreport 10: 1205-1207, 1999.
60. Klein JD, Murrell BP, Tucker S, Kim Y, Sands JM. Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension. Am J Physiol Renal Physiol 291: F952-F959, 2006.
61. Klussmann E, Maric K, Rosenthal W. The mechanisms of aquaporin control in the renal collecting duct. Rev Physiol Biochem Pharmacol 141: 33-95, 2000.
62. Knepper MA, Nielsen S. Kinetic model of water and urea permeability regulation by vasopressin in collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 265: F214-F224, 1993.
63. Kozniewska E, Szczepánska-Sadowska E. V2-like receptors mediate cerebral blood flow increase following vasopressin administration in rats. J Cardiovasc Pharmacol 15: 579-585, 1990.
64. Kristiansen M, Knudsen GPS, Bathum L, Naumova AK, Sørensen TIA, Brix TH, Svendsen AJ, Christensen K, Kyvik KO, Ørstavik KH. Twin study of genetic and aging effects on X chromosome inactivation. Eur J Hum Genet 13: 599-606, 2005.
65. Kumagami H, Loewenheim H, Beitz E, Wild K, Schwartz H, Yamashita K, Schultz J, Paysan J, Zenner HP, Ruppersberg JP. The effect of anti-diuretic hormone on the endolymphatic sac of the inner ear. Pflügers Arch 436: 970-975, 1998.
66. Liu J, Sharma N, Zheng W, Ji H, Tam H, Wu X, Manigrasso MB, Sandberg K, Verbalis JG. Sex differences in vasopressin V2 receptor expression and vasopressin-induced antidiuresis. Am J Physiol Renal Physiol 300: F433-F440, 2011.
67. Liu X, Nakayama S, Amiry-Moghaddam M, Ottersen OP, Bhardwaj A. Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. Neurocrit Care 12: 124-131, 2010.
68. László FA, László FJ, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43: 73-108, 1991.
69. Maekawa C, Kitahara T, Kizawa K, Okazaki S, Kamakura T, Horii A, Imai T, Doi K, Inohara H, Kiyama H. Expression and translocation of aquaporin-2 in the endolymphatic sac in patients with Meniere's disease. J Neuroendocrinol 22: 1157-1164, 2010.
70. Malerbi DA, Fragoso MC, Vieira Filho AH, Brenlha EM, Mendonça BB. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab 81: 2233-2237, 1996.
71. Malerbi DA, Mendonça BB, Liberman B, Toledo SP, Corradini MC, Cunha-Neto MB, Fragoso MC, Wajchenberg BL. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 38: 463-472, 1993.
72. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170: 473-512, 2008.
73. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30: 81-93, 1975.
74. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-Darginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1: 869-872, 1977.
75. Medina P, Segarra G, Vila JM, Chuan P, Domenech C, Lluch S. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens 12: 188-193, 1999.
76. Migeon BR. X inactivation, female mosaicism, and sex differences in renal diseases. J Am Soc Nephrol 19: 2052-2059, 2008.
77. Miller RL, Sandoval PC, Pisitkun T, Knepper MA, Hoffert JD. Vasopressin inhibits apoptosis in renal collecting duct cells. Am J Physiol Renal Physiol 304: F177-F188, 2013.
78. Moeller HB, Fenton RA. Cell biology of vasopressin-regulated aquaporin-2 trafficking. Pflügers Arch 464: 133-144, 2012.
79. Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem 270: 25771-25777, 1995.
80. Mutig K, Paliege A, Kahl T, Jöns T, Müller-Esterl W, Bachmann S. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol 293: F1166-F1177, 2007.
81. Müller D, Florkowski H, Chavez-Kattau K, Carlsson G, Eggert P. The effect of desmopressin on short-term memory in children with primary nocturnal enuresis. J Urol 166: 2432-2434, 2001.
82. Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA 90: 11663-11667, 1993.
83. Nielsen S, Knepper MA. Vasopressin activates collecting duct urea transporters and water channels by distinct physical processes. Am J Physiol Renal Fluid Electrolyte Physiol 265: F204-F213, 1993.
84. Nielsen S, Marples D, Frøkiaer J, Knepper M, Agre P. The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Kidney Int 49: 1718-1723, 1996.
85. Noh JM, Park W, Huh SJ, Cho EY, Choi Y, Lee JH, Bae DS. Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. J Gynecol Oncol 20: 215-220, 2009.
86. North WG. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol 85: 27S-40S, 2000.
87. North WG, Fay MJ, Du J. All three vasopressin receptor sub-types are expressed by small-cell carcinoma. Adv Exp Med Biol 449: 335-338, 1998.
88. North WG, Fay MJ, Du J. MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20: 837-842, 1999.
89. North WG, Fay MJ, Longo KA, Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res 58: 1866-1871, 1998.
90. Nossent AY, Robben JH, Deen PMT, Vos HL, Rosendaal FR, Doggen CJM, Hansen JL, Sheikh SP, Bertina RM, Eikenboom JCJ. Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von willebrand factor levels. J Thromb Haemost 8: 1547-1554, 2010.
91. Oligny-Longpré G, Corbani M, Zhou J, Hogue M, Guillon G, Bouvier M. Engagement of-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation. Proc Natl Acad Sci USA 109: E1028-E1037, 2012.
92. Ostrowski NL, Young WS, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology 133: 1849-1859, 1993.
93. Pinto CS, Reif GA, Nivens E, White C, Wallace DP. Calmodulinsensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl-secretion by human autosomal dominant polycystic kidney cells. Am J Physiol Renal Physiol 303: F1412-F1424, 2012.
94. Pisitkun T, Jacob V, Schleicher SM, Chou C, Yu M, Knepper MA. Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD. Am J Physiol Renal Physiol 295: F1030-F1043, 2008.
95. Péqueux C, Breton C, Hagelstein M, Geenen V, Legros J. Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung. Lung Cancer 50: 177-188, 2005.
96. Regard JB, Sato IT, Coughlin SR. Anatomical profiling of g proteincoupled receptor expression. Cell 135: 561-571, 2008.
97. Renault NK, Dyack S, Dobson MJ, Costa T, Lam WL, Greer WL. Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females. Eur J Hum Genet 15: 628-637, 2007.
98. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des 11: 205-225, 2005.
99. Rowe JW, Shelton RL, Helderman JH, Vestal RE, Robertson GL. Influence of the emetic reflex on vasopressin release in man. Kidney Int 16: 729-735, 1979.
100. Sadeghi H, Birnbaumer M. O-glycosylation of the V2 vasopressin receptor. Glycobiology 9: 731-737, 1999.
101. Sadeghi HM, Innamorati G, Dagarag M, Birnbaumer M. Palmitoylation of the V2 vasopressin receptor. Mol Pharmacol 52: 21-29, 1997.
102. Saigusa T, Reichert R, Guare J, Siroky BJ, Gooz M, Steele S, Fenton RA, Bell PD, Kolb RJ. Collecting duct cells that lack normal cilia have mislocalized vasopressin-2 receptors. Am J Physiol Renal Physiol 302: F801-F808, 2012.
103. Sasaki S, Imai M. Effects of vasopressin on water and NaCl transport across the in vitro perfused medullary thick ascending limb of Henle's loop of mouse, rat, and rabbit kidneys. Pflügers Arch 383: 215-221, 1980.
104. Schülein R, Zühlke K, Oksche A, Hermosilla R, Furkert J, Rosenthal W. The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues. FEBS Lett 466: 101-106, 2000.
105. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res 51: 3621-3623, 1991.
106. Star RA, Nonoguchi H, Balaban R, Knepper MA. Calcium and cyclic adenosine monophosphate as second messengers for vasopressin in the rat inner medullary collecting duct. J Clin Invest 81: 1879-1888, 1988.
107. Stegner H, Artman HG, Leake RD, Fisher DA. Does dDAVP (1-desamino-8-D-arginine-vasopressin) cross the blood-CSF barrier? Neuroendocrinology 37: 262-265, 1983.
108. Stonebraker JS, Bolton-Maggs PHB, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16: 20-32, 2010.
109. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 269: 27088-27092, 1994.
110. Sørensen PS, Vilhardt H, Gjerris F, Warberg J. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (dDAVP) in patients with acquired, communicating hydrocephalus. Eur J Clin Invest 14: 435-439, 1984.
111. Taguchi D, Takeda T, Kakigi A, Takumida M, Nishioka R, Kitano H. Expressions of aquaporin-2, vasopressin type 2 receptor, transient receptor potential channel vanilloid (TRPV)1, and TRPV4 in the human endolymphatic sac. Laryngoscope 117: 695-698, 2007.
112. Takeda T, Sawada S, Takeda S, Kitano H, Suzuki M, Kakigi A, Takeuchi S. The effects of v2 antagonist (OPC-31260) on endolymphatic hydrops. Hear Res 182: 9-18, 2003.
113. Takeda T, Takeda S, Kakigi A, Okada T, Nishioka R, Taguchi D, Nishimura M, Nakatani H. Hormonal aspects of Ménière's disease on the basis of clinical and experimental studies. ORL J Otorhinolaryngol Relat Spec 71, Suppl 1: 1-9, 2010.
114. Takeda T, Takeda S, Kitano H, Okada T, Kakigi A. Endolymphatic hydrops induced by chronic administration of vasopressin. Hear Res 140: 1-6, 2000.
115. Takumida M, Kakigi A, Egami N, Nishioka R, Anniko M. Localization of aquaporins 1, 2, and 3 and vasopressin type 2 receptor in the mouse inner ear. Acta Otolaryngol 132: 807-813, 2012.
116. Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC, Luqmani YA. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50: 7882-7886, 1990.
117. Thielen A, Oueslati M, Hermosilla R, Krause G, Oksche A, Rosenthal W, Schülein R. The hydrophobic amino acid residues in the membrane-proximal C tail of the G protein-coupled vasopressin V2 receptor are necessary for transport-competent receptor folding. FEBS Lett 579: 5227-5235, 2005.
118. Tian Y, Serino R, Verbalis JG. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration. Am J Physiol Renal Physiol 287: F797-F805, 2004.
119. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012.
120. Tsikunov SG, Belokoskova SG. Psychophysiological analysis of the influence of vasopressin on speech in patients with post-stroke aphasias. Span J Psychol 10: 178-188, 2007.
121. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F. Towards a knowledge-based human protein atlas. Nat Biotechnol 28: 1248-1250, 2010.
122. Van Balkom BWM, van Raak M, Breton S, Pastor-Soler N, Bouley R, van der Sluijs P, Brown D, Deen PMT. Hypertonicity is involved in redirecting the aquaporin-2 water channel into the basolateral, instead of the apical, plasma membrane of renal epithelial cells. J Biol Chem 278: 1101-1107, 2003.
123. Van den Ouweland AM, Knoop MT, Knoers VV, Markslag PW, Rocchi M, Warren ST, Ropers HH, Fahrenholz F, Monnens LA, van Oost BA. Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type 2 receptor gene (AVPR2) in the Xq28 region. Genomics 13: 1350-1352, 1992.
124. Verbalis JG. Escape from antidiuresis: a good story. Kidney Int 60: 1608-1610, 2001.
125. Verney EB. The antidiuretic hormone and the factors which determine its release. Proc R Soc Lond B Biol Sci 135: 25-106, 1947.
126. Wang F, Tang K, Yen Y, Ho DM, Yang A, Hwang C, Lin H, Won JGS. Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours. Clin Endocrinol (Oxf) 76: 253-263, 2012.
127. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn 31: 441-447, 2012.
128. Wickramasinghe SN, Valdimarsson H, Williams B. Interaction between a synthetic analogue of vasopressin and human peripheral blood lymphocytes. J Clin Lab Immunol 7: 67-70, 1982.
129. Willard H. The sex chromosomes and X chromosome inactivation. In: The Metabolic and Molecular Bases of Inherited Disease, edited by Scriver C, Beaudet A, Sly W, Valle D. New York: McGraw-Hill, 1995, p. 719-735.
130. Woll PJ, Rozengurt E. Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. Biochem Biophys Res Commun 164: 66-73, 1989.
131. Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP. Gender difference in efficacy and dose response in japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int 111: 474-484, 2013.
132. Yamaguchi Y, Yamada K, Suzuki T, Wu Y, Kita K, Takahashi S, Ichinose M, Suzuki N. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP). Am J Physiol Endocrinol Metab 287: E970-E976, 2004.
133. Yip K. Coupling of vasopressin-induced intracellular Ca2_ mobilization and apical exocytosis in perfused rat kidney collecting duct. J Physiol 538: 891-899, 2002.
134. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am J Med 74: 265-271, 1983.
135. Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28: 503-508, 1979.